GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs.

GSK) chronic obstructive pulmonary disease (COPD) treatments, Trelegy Ellipta and Breo Ellipta. Under the Inflation Reduction Act, CMS is negotiating prices for select Medicare Part D drugs. In the ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added ... solid sales growth of the asthma inhaler Trelegy Ellipta across all regions, reflecting patient ...

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

Elizabeth Warren (D-Mass.) is asking a federal watchdog to investigate GSK for replacing a popular asthma inhaler with a so-called authorized generic at a much higher price in order to avoid ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a prescription drug on LinkedIn. A panel of leaders at the PMCPA, pharma’s ...

Canada has announced a deal to secure 500K doses of GSK’s (NYSE:GSK) avian influenza vaccine for humans as the country steps up efforts to protect at-risk individuals and bolster its federal ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine sales falling, some market participants say it may draw in activist ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...